CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
420.42MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9120xvs all stocks
52-Week Change
166.84%vs all stocks
Market Capitalization
420.42MUSDvs all stocks (USD)
Enterprise Value
691.05MUSDvs all stocks (USD)
Forward P/E
-11.50xvs Biotechnology peers
Price to Book (MRQ)
6.93xvs Biotechnology peers
Enterprise to EBITDA
-13.14xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-32.74%vs Biotechnology peers
Return on Equity (TTM)
-51.71%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-57.91MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-38.14MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-18.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-56.38MUSDvs all stocks (USD)
Pre-tax Income
-52.60MUSDFY2025 · Dec 31, 2025Net Income
-52.60MUSDFY2025 · Dec 31, 2025EBIT
-52.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-52.60MUSDFY2025 · Dec 31, 2025Research & Development
32.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.71MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-1.34USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.34USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-30.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
97.56MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.60MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.88MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
24.28MSharesUpdated Jul 19, 2026Shares Short
1.79MSharesUpdated Jul 19, 2026Short Ratio
1.46daysvs all stocks
Short % of Shares Outstanding
6.82%vs all stocks
% Held by Insiders
0.15%vs all stocks
% Held by Institutions
76.46%vs all stocks
Total Cash (MRQ)
118.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.32USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
14.52xvs Biotechnology peers
Book Value per Share (MRQ)
2.29USDUpdated Jul 19, 2026Total Assets
104.23MUSDvs all stocks (USD)
Total Current Assets
104.23MUSDFY2025 · Dec 31, 2025Total Liabilities
7.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
7.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
97.56MUSDFY2025 · Dec 31, 2025Accounts Payable
6.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-367.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
97.07MUSDvs all stocks (USD)
52-Week Low
5.77USDUpdated Jul 19, 202652-Week High
19.40USDUpdated Jul 19, 202652-Week Change
166.84%vs all stocks
Beta
0.9120xvs all stocks
50-Day MA
12.91USDUpdated Jul 19, 2026200-Day MA
11.88USDUpdated Jul 19, 2026Avg 10-Day Volume
1.22MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.32MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.41USDUpdated Jul 19, 2026Other Income / Expense
-33.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Halo Microelectronics Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets